期刊文献+

注射用帕尼培南倍他米隆与4种临床常用输液的配伍稳定性 被引量:2

Compatible stability of panipenem and betamipron for injection with four common clinical infusion fluids
原文传递
导出
摘要 目的建立注射用帕尼培南倍他米隆含量的测定方法,并研究与4种常用输液的配伍稳定性。方法用RP-HPLC法测定配伍后不同时间点的帕尼培南和倍他米隆的含量,同时考察其外观、颜色、pH值变化。结果室温下放置6h,其含量、pH值、外观均无明显变化,但与10%葡萄糖注射剂和葡萄糖氯化钠溶液配伍12h后,溶液颜色明显变黄。结论注射用帕尼培南倍他米隆与4种输液配伍在6h内稳定,但与10%葡萄糖注射剂和葡萄糖氯化钠溶液配伍长时间放置需谨慎。 AIM To establish a method for the determination of panipenem and betamipron for injection,research the stability of panipenem and betamipron for injection with the four common clinical infusion fluids.METHODS The contents of panipenem and betamipron in the fluids were determined at different time points by RP-HPLC,the outward appearance,color variety and pH value were investigated in the same time.RESULTS Within 6 h,the contents,the outward appearance and the pH value of panipenem and betamipron had no apparent changes at room temperature;but after 12 h,the color variety could be observed clearly in 10%glucose,the same color variety could be observed in glucose and sodium chloride injection.CONCLUSION Panipenem and betamipron for injection are stable in the four fluids within 6 h,but it must be used carefully with the 10%glucose and glucose and sodium chloride injection after a long time delay.
出处 《中国临床药学杂志》 CAS 2011年第2期102-105,共4页 Chinese Journal of Clinical Pharmacy
关键词 帕尼培南 倍他米隆 高效液相色谱 稳定性 panipenem betamipron HPLC stability
  • 相关文献

参考文献7

二级参考文献99

共引文献63

同被引文献18

  • 1赵可新,胡建平,单靖珊,马骐,葛军.盐酸吉西他滨临床应用进展[J].中国医药导报,2006,3(36):13-15. 被引量:12
  • 2毛璐,甄健存,陈志刚,崔蔚.静脉滴注药物中不溶性微粒的考察[J].中国药学杂志,2006,41(1):45-47. 被引量:25
  • 3李健和,胡弘霞,黎银波,崔巍.注射用间苯三酚的制备、质量控制及稳定性考察[J].中国药房,2007,18(4):286-288. 被引量:7
  • 4彭文达,李健和,黎银波,彭六保.间苯三酚注射液的研制[J].中国药物与临床,2007,7(4):315-317. 被引量:14
  • 5汤光,李大魁.现代临床药物学[M].北京:化学工业出版社,2008:62-63.
  • 6Baek JH, Kim H, Ahn JJ, et al. Prospective phase II trial of a combi- nation of gemcitabinc and UFI" as first-line treatment in elderly patients with advanced non-small cell lung cancer[J]. Lung Cancer, ).Oil, In Press.
  • 7Bdani C, Goss G, Blumensehein G. Recent clinical developments andrationale for combining targeted agents in non-small cell lung cancer (NSCLC)[J]. Cancer Treat Rev, 2012, 38(3) :173.
  • 8Terashima K, Demizu Y, Hashimoto N, et al. A phase I / I1 study of gemcitabinconcurrent proton radiotherapy for locally advanced pancre- atic cancer without distant metastasis[J]. Radiother Oncol, 2012, 103 (1):25.
  • 9Salem S, Abou-Tadxsh F, Saeed N, et al. Involvement of p53 in gem- eitabine mediated eytoto:deity and radiesensitivity in breast cancer cell lines[J]. Gene, 2012, 498(2) :300.
  • 10Keith B,Xu Y, Grem JL. Measurement of the anti-cancer agent gemc- itabine in human pl~ma by high performance liquid chromatography[J]. J Chromatogr B, 2003, 785: 65.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部